to
the region; nine of those drugs came from research done by the U.S. military
for the Vietnam War or from research for the livestock and pet market.How do
we make private companies care as much about sleeping sickness (on which no
major company is doing research) as they do about canine Alzheimer’s (for
which Pfizer already has a drug)? Change the incentives. In 2005, British Prime
Minister Gordon Brown embraced an idea that economists have long kicked
around: Identify a disease that primarily afflicts a poor part of the world and then
offer a large cash prize to the first firm that develops
a vaccine that meets
predetermined criteria (e.g., is effective, is safe for use in children, doesn’t need
refrigeration, etc.). Brown’s plan was actually more sophisticated; he proposed
that rich governments precommit to buying a certain number of doses of the
“winning” vaccine at a certain price. Poor people would get lifesaving drugs.
The pharmaceutical company would get what it
needs to justify the vaccine
research: a return on investment, just as it does when developing drugs that
consumers in rich countries will buy. (The British government has been thinking
this way for a long time. In 1714, after two thousand sailors drowned when a
fleet got lost,
crashed into the rocky coast, and sunk, the British government
offered 20,000 pounds to anyone who developed an instrument for measuring
longitude at sea. The prize led to the invention of the chronometer.)
17
The other hope for poor countries in the tropics, says Mr. Sachs, is to step out
of the trap of subsistence agriculture by opening their
economies to the rest of
the world. He notes, “If the country can escape to higher incomes via non-
agricultural sectors (e.g., through a large expansion of manufactured exports),
the burdens of the tropics can be lifted.”
18
Which brings us once again to our old
friend trade.
Dostları ilə paylaş: